Liu, X., Munro, A. P., Feng, S., Janani, L., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dejnirattisai, W., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., Libri, V., Llewelyn, M. J., McGregor, A. C., Minassian, A. M., Moore, P., Mughal, M., Mujadidi, Y. F., Holliday, K., Osanlou, O., Osanlou, R., Owens, D. R., Pacurar, M., Palfreeman, A., Pan, D., Rampling, T., Regan, K., Saich, S., Serafimova, T., Saralaya, D., Screaton, G. R., Sharma, S., Sheridan, R., Sturdy, A., Supasa, P., Thomson, E. C., Todd, S., Twelves, C., Read, R. C., Charlton, S., Hallis, B., Ramsay, M., Andrews, N., Lambe, T., Nguyen-Van-Tam, J. S., Cornelius, V., Snape, M. D., Faust, S. N., & , (2023). corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795–813, 5511]. Journal of infection, 86(5), 540–541. http://access.bl.uk/ark:/81055/vdc_100184744767.0x000053